NextCure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by NextCure, Inc. on March 30, 2020, reporting events that occurred on March 25, 2020. The filing addresses changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Timothy M. Shannon, M.D., resigned from the Board of Directors effective March 25, 2020. Dr. Shannon served as Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: Garry A. Nicholson was appointed to the Board to fill the vacancy created by Dr. Shannon's resignation. Mr. Nicholson serves as a Class I director until the 2020 annual meeting of stockholders.
- Committee Assignments: Mr. Nicholson has been appointed as a member of the Audit Committee.
Outlook, Risks, and Management Commentary
Management highlighted Mr. Nicholson's extensive experience in the biopharmaceutical sector, including roles as Chairman of G1 Therapeutics, Inc., and former President of Pfizer Oncology. He will be compensated in accordance with the Company's Non-Employee Director Compensation Program and has entered into a customary indemnification agreement. No specific risks, contingencies, or unusual financial items were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of Timothy M. Shannon's resignation (March 25, 2020).
- Verify Garry A. Nicholson's new role as a Class I director and Audit Committee member.
- Review the attached press release (Exhibit 99.1) for additional details on the Board composition.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial metrics.